دورية أكاديمية
CRITICAL ANALYSIS OF ANTI-TNF USE IN THE ERA OF NEW BIOLOGICAL AGENTS IN INFLAMMATORY BOWEL DISEASE.
| العنوان: | CRITICAL ANALYSIS OF ANTI-TNF USE IN THE ERA OF NEW BIOLOGICAL AGENTS IN INFLAMMATORY BOWEL DISEASE. |
|---|---|
| المؤلفون: | Lima CCG; Universidade de São Paulo, Faculdade de Medicina, Departamento de Gastroenterologia, São Paulo, SP, Brasil., Queiroz NSF; Universidade de São Paulo, Faculdade de Medicina, Departamento de Gastroenterologia, São Paulo, SP, Brasil., Sobrado CW; Universidade de São Paulo, Faculdade de Medicina, Departamento de Gastroenterologia e Divisão de Coloproctologia, São Paulo, SP, Brasil., Silva GLR; Universidade de São Paulo, Faculdade de Medicina, Departamento de Gastroenterologia e Divisão de Endoscopia Digestiva, São Paulo, SP, Brasil., Nahas SC; Universidade de São Paulo, Faculdade de Medicina, Departamento de Gastroenterologia e Divisão de Coloproctologia, São Paulo, SP, Brasil. |
| المصدر: | Arquivos de gastroenterologia [Arq Gastroenterol] 2020 Jul-Sep; Vol. 57 (3), pp. 323-332. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia Country of Publication: Brazil NLM ID: 15310600R Publication Model: Print Cited Medium: Internet ISSN: 1678-4219 (Electronic) Linking ISSN: 00042803 NLM ISO Abbreviation: Arq Gastroenterol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: São Paulo, Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia. |
| مواضيع طبية MeSH: | Inflammatory Bowel Diseases*/drug therapy, Biological Factors ; Humans ; Quality of Life ; Tumor Necrosis Factor-alpha |
| مستخلص: | Background: Inflammatory bowel diseases (IBD), both Crohn's disease and ulcerative colitis, are chronic immune-mediated diseases that present a relapsing and remitting course and requires long-term treatment. Anti-tumor necrosis factor (anti-TNF) therapy has changed the management of the disease by reducing the need for hospitalizations, surgeries and improving patient´s quality of life. Objective: The aim of this review is to discuss the role of anti-TNF agents in IBD, highlighting the situations where its use as first-line therapy would be appropriate. Methods: Narrative review summarizing the best available evidence on the topic based on searches in databases such as MedLine and PubMed up to April 2020 using the following keywords: "inflammatory bowel disease'', "anti-TNF agents" and ''biologic therapy''. Conclusion: Biological therapy remains the cornerstone in the treatment of IBD. In the absence of head-to-head comparisons, the choice of the biological agent may be challenging and should take into account several variables. Anti-TNF agents should be considered as first line therapy in specific scenarios such as acute severe ulcerative colitis, fistulizing Crohn's disease and extra-intestinal manifestations of IBD, given the strong body of evidence supporting its efficacy and safety in these situations. |
| المشرفين على المادة: | 0 (Biological Factors) 0 (Tumor Necrosis Factor-alpha) |
| تواريخ الأحداث: | Date Created: 20201007 Date Completed: 20210115 Latest Revision: 20210115 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1590/S0004-2803.202000000-59 |
| PMID: | 33027484 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1678-4219 |
|---|---|
| DOI: | 10.1590/S0004-2803.202000000-59 |